ReviewBrain pathology (Zurich, Switzerland)2024
Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies.
Review in Brain pathology (Zurich, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Management and long-term haematological and neurological outcomes of Immunoglobulin M and Waldenström's macroglobulinaemia-related neuropathy: A single-centre experience.British journal of haematology · 2026Article
- Cladribine treatment in chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: two case reports.Frontiers in immunology · 2026Article
- Neuromuscular ultrasound of the brachial plexus: know-how, know-when.Clinical neurophysiology practice · 2026Review
- Autoimmune Neuromuscular Disorders at a Molecular Crossroad: Linking Pathogenesis to Targeted Immunotherapy.International journal of molecular sciences · 2025Review
- Macrophage-derived exosomes in autoimmune diseases: mechanistic insights and therapeutic implications.Immunologic research · 2025Review
- The Potential Role of Adipose-Derived Stem Cells in Regeneration of Peripheral Nerves.Neurology international · 2025Review
- The Discovery of Autoimmune Nodopathies and the Impact of IgG4 Antibodies in Autoimmune Neurology.Neurology(R) neuroimmunology & neuroinflammation · 2025Review
- Super-resolution of nodal and paranodal disruption in anti-pan-neurofascin-associated autoimmune nodopathy.Frontiers in immunology · 2025Article
- Meeting report of the 20th International Congress of Neuropathology (ICN) 2023 in Berlin.Brain pathology (Zurich, Switzerland) · 2024Article
- Pathology explains various mechanisms of auto-immune inflammatory peripheral neuropathies.Brain pathology (Zurich, Switzerland) · 2024Review
- Rehabilitation of Peripheral Neuropathies: From Lexical Analysis of the Literature to Identification of Clinical Protocols.Journal of clinical medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune neuropathies are a heterogeneous group of rare and disabling diseases in which the immune system is thought to target antigens in the peripheral nervous system: they usually respond to immune therapies. Guillain-Barré syndrome is divided into several subtypes including "acute inflammatory demyelinating polyradiculoneuropathy," "acute motor axonal neuropathy," "acute motor sensory neuropathy," and other variants. Chronic forms such as chronic inflammatory demyelinating polyneuropathy (CIDP) and other subtypes and polyneuropathy associated with IgM monoclonal gammopathy; autoimmune nodopathies also belong to this group of auto-immune neuropathies. It has been shown that immunoglobulin G from the serum of about 30% of CIDP patients immunolabels nodes of Ranvier or paranodes of myelinated axons. Whatever the cause of myelin damage of the peripheral nervous system, the initial attack on myelin by a dysimmune process may begin either at the internodal area or in the paranodal and nodal regions. The term "nodoparanodopathy" was first applied to some "axonal Guillain-Barré syndrome" subtypes, then extended to cases classified as CIDP bearing IgG4 antibodies against paranodal axoglial proteins. In these cases, paranodal dissection develops in the absence of macrophage-induced demyelination. In contrast, the mechanisms of demyelination of other dysimmune neuropathies induced by macrophages are unexplained, as no antibodies have been identified in such cases. The main objective of this presentation is to show that the pathology illustrates, confirms, and may explain such mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.